Navigation Links
IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail

NEW YORK, Jan. 26 /PRNewswire/ -- Fifty percent of clinical trial management professionals in the life sciences industry still share high-value, proprietary company information via e-mail, while others do so via fax (15 percent) or overnight courier (14 percent), according to a recent IntraLinks(R) poll.

Respondents who were considering web-based solutions for exchanging clinical trial information with outside parties indicated their primary concerns were security (40 percent), ease and flexibility of use (23 percent), speed of information sharing (17 percent), standardization across the enterprise (7 percent) and shipping/travel cost savings (7 percent).

In addition, respondents indicated that the greatest challenges they face when starting a new study or clinical trial are getting research sites onboard quickly (61 percent); reducing cycle time (22 percent); and exchanging information with all sites efficiently (12 percent).

"Executives may not realize that study start-up communication and management can be made simpler, faster and more secure by employing online solutions," said Alison Shurell, vice president of life sciences product marketing for IntraLinks. "Using an online workspace enables sponsors, CROs, sites, IRBs and others in a clinical trial to exchange information instantaneously in the most secure environment available. Our life sciences clients who have shifted the clinical trial process to an online solution have reported tremendous improvements in overall productivity and efficiency."

More than 50 executives from pharmaceutical, biotechnology, medical device and healthcare companies and CROs responded to polling questions for a recent webcast titled "Site Activation: How to Reduce Costs and Shorten Study Start-up Time." Sixty three percent of the polling respondents are involved in the management of clinical trials for their companies.

Executives from Quintiles Transnational and Copernicus Group IRB presented during the webcast, reporting that they employ online workspace technology to expedite the exchange of critical information during clinical trials. Both organizations indicated that significant time and money savings have been realized as a result.

About IntraLinks

IntraLinks(R) On-Demand Workspaces(TM) connect business communities and accelerate the intelligent flow of information and documents among participants. Through IntraLinks' secure, neutral, online environments, companies are better able to compete globally by accelerating essential business processes, simplifying communication and fostering rapid workflow.

IntraLinks is easily accessible anywhere, anytime using a web browser. Since 1997, more than 750,000 participants representing over 90,000 organizations worldwide have used IntraLinks On-Demand Workspaces(TM) to communicate and collaborate on thousands of projects and transactions. IntraLinks has been adopted widely in the financial services and pharmaceutical industries, where its clients include AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank, FDIC, TD Securities, Thomas Weisel Partners and WestLB, among hundreds of others. Founded in 1996, IntraLinks is headquartered in New York with offices around the world. For more information, visit

SOURCE IntraLinks
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... KONG, Nov. 23, 2015 China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended September 30, 2015. --> ... , Revenues for the second quarter of fiscal ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):